Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.40 |
| ▸ | PPARA | Q07869 | 8/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497351 | 0.89 | POLB (0.43) | PPARDPPARAPPARGNAMPTLMNA | |
| SCHEMBL6504374 | 0.84 | OPRK1 (0.36) | PPARDPPARAPPARGNAMPTLMNA | |
| SCHEMBL6527212 | 0.80 | PPARA (0.45) | PPARDPPARAPPARG | |
| SCHEMBL6498808 | 0.79 | PPARA (0.44) | PPARDPPARAPPARG | |
| SCHEMBL6502670 | 0.78 | PPARA (0.42) | PPARDPPARAPPARG | |
| SCHEMBL6505343 | 0.78 | POLB (0.44) | PPARDPPARAPPARGLMNATP53 | |
| SCHEMBL6528332 | 0.77 | PPARA (0.43) | PPARDPPARAPPARG | |
| SCHEMBL6496490 | 0.77 | POLB (0.65) | LMNASMN1; SMN2TP53MAPTPOLB | |
| SCHEMBL6503794 | 0.77 | PPARA (0.46) | PPARDPPARAPPARG | |
| SCHEMBL6505813 | 0.76 | PPARA (0.43) | PPARDPPARAPPARGLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6509507-B2 | Reacting a 6-membered aromatic ring with 1,4- position ester or benzylic OH groups with a second aromatic in a palladium catalyzed cross-coupling; electroluminescence | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2003-01-21 | — | — | US | claimed |
| US-20020087030-A1 | Polymerizable biaryls, process for their preparation and their use | MERCK PATENT GMBH (DE) | 2002-07-04 | — | — | US | claimed |
| EP-0944569-B1 | POLYMERIZABLE BIARYLS, METHOD FOR THE PRODUCTION AND USE THEREOF | CELANESE VENTURES GMBH (DE) | 2002-04-10 | — | — | EP | claimed |
| US-6323373-B1 | USED TO OBTAIN POLYMERS WHICH ARE USED AS ELECTROLUMINESCENCE MATERIALS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2001-11-27 | — | — | US | claimed |
| US-6884821-B1 | Carboxylic acid derivatives and drugs containing the same | EISAI CO., LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-6872740-B2 | Use of 2-amino-4-heteroarylethyl-thiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20030225140-A1 | 4-(heteroarylethyl)-4,5-dihydro-1,3-thiazol-2-ylamine or salt, useful for treating an illness, which involves an abnormal production of nitric oxide (NO) by induction of an inducible NO-synthase | AVENTIS PHARMA S.A. (FR) | 2003-12-04 | — | — | US | disclosed |
| US-6509507-B2 | Reacting a 6-membered aromatic ring with 1,4- position ester or benzylic OH groups with a second aromatic in a palladium catalyzed cross-coupling; electroluminescence | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2003-01-21 | — | — | US | disclosed |
| US-20020087030-A1 | Polymerizable biaryls, process for their preparation and their use | MERCK PATENT GMBH (DE) | 2002-07-04 | — | — | US | disclosed |
| EP-1216980-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-6323373-B1 | USED TO OBTAIN POLYMERS WHICH ARE USED AS ELECTROLUMINESCENCE MATERIALS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225140-A1 | 4-(heteroarylethyl)-4,5-dihydro-1,3-thiazol-2-ylamine or salt, useful for treating an illness, which involves an abnormal production of nitric oxide (NO) by induction of an inducible NO-synthase | PTGS1, PTGIS, NOS1 | PPARD 2136/4885PPARA 1611/4885PPARG 1483/4885 |
| US-20020087030-A1 | Polymerizable biaryls, process for their preparation and their use | PAH, TYR, PAICS | PPARD 1926/4885PPARA 1040/4885PPARG 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.